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ABSTRACT
Objectives: This study identiﬁes latent classes deﬁned by
varying degrees of adherence to antipsychotic drug therapy
and examines the sociodemographic, clinical, and resource
utilization correlates associated with membership in each
adherence class.
Data and methods: Patient-level data were drawn from the
1994 to 2003, 100%-sample California Medicaid fee-for-
service paid claims data for patients with schizophrenia
(N = 36,195). The date of the ﬁrst antipsychotic medication
ﬁlled after January 1, 1999 was then used to divide each
patient’s data into a 6-month preindex (baseline) and a
12-month postindex (follow-up) period. Three categorical
adherence indicators—a dichotomous variable of medication
possession ratio greater than 0.80, the number of anti-
psychotic treatment attempts, and time to a change in anti-
psychotic medications—and two covariates—a categorical
variable of duration of therapy and a dichotomous variable
of polypharmacy—were used in the latent class model.
Results: A three-class model returned the lowest values for
all the information criteria and was therefore interpreted as
follows: The prevalence rates of the latent classes were 1)
14.8% for the adherent; 2) 20.7% for the partially adherent;
and 3) 64.5% for the nonadherent. Membership in the non-
adherent class was associated with minority ethnicity, being
female, eligibility due to welfare status, prior hospitaliza-
tions, and a higher number of prior treatment episodes.
Membership in the partially adherent class was associated
with higher use of outpatient care, higher rates of depot
antipsychotic drug use, and polypharmacy.
Conclusion: Multiple indicators of adherence to antipsy-
chotic medication can be used to deﬁne classes of adherence
that are associated with patient characteristics and distinct
patterns of prior health-care use.
Keywords: adherence, latent class analysis, Medicaid,
schizophrenia.
Introduction
Antipsychotic medication treatment can improve out-
comes in schizophrenia, but poor outcomes have been
associated with nonadherence to antipsychotic drug
therapy. Nonadherence can precipitate clinical (symp-
tomatic) relapse and trigger intensive resource utiliza-
tion that signiﬁcantly increases the total costs of care.
Several studies using the California Medicaid (Medi-
Cal) database have shown negative effects of anti-
psychotic nonadherence. For example, Gilmer et al.
reported that only 41% of Medi-Cal patients take their
antipsychotic medication on a regular basis and sig-
niﬁcantly higher outpatient and hospital medical costs
are incurred to the patients who are not regularly
adherent to their prescribed drug regimen [1]. Weiden
et al. found an association between partial adherence
and hospitalization risk among Medi-Cal patients with
schizophrenia across a continuum of adherence behav-
iors [2]. McCombs et al. reported that delays in start-
ing antipsychotic therapy and changes in therapy were
associated with a signiﬁcantly higher total cost of
health care over 1 year using a sample of Medi-Cal
patients with schizophrenia [3]. Patients who received
some form of therapy, with no delay, exhibited lower
costs than untreated patients, especially for psychiatric
hospital treatment costs.
Adherence to medication has been measured in
numerous ways [4], with the most prevalent measures
being patient self-report, pill count, use of electronic
monitoring devices, and review of prescription records
and claims. Taken individually, none of these methods
is error-proof (totally reliable), even direct patient
observation. Therefore, clinicians and researchers
must consider a range of adherence indicators when
making determinations of whether or not the patient is
adherent to the prescribed drug therapy.
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Many studies in the published literature deﬁne non-
adherence as either deliberate or unintended patient
behavior that is not consistent with medical advice.
For example, Marland deﬁned nonadherence as occur-
ring when patients passively failed to keep to their
prescribed medication regime [5], while Blackwell
states that nonadherence is the failure to comply with
the prescribed medication regime [6]. In a large obser-
vational study, failure to reﬁll was considered the
most reliable objective measure of adherence to drug
therapy [7]. McCombs et al. used medication
persistence—measured as the time from the initiation
of drug therapy to discontinuation of therapy—as their
measure of medication adherence [8].
This study uses a statistical model employing mul-
tiple observable indicators of adherence to identify
groups of patient adherence. Speciﬁcally, latent class
analysis (LCA) is used to deﬁne otherwise unobserved
groups of patients with different adherence behaviors
that may be complex and nontrivial in their structure.
The resulting adherence typology system is then
used to examine the sociodemographic, clinical, and
resource utilization/economic correlates of adherence
classes and to document the relationship between
adherence and the patient’s health service utilization
during the 1-year follow-up period across the
adherence/nonadherence latent classes.
The conventional way of studying adherence is clas-
sifying patients into trivial groups of adherence, typi-
cally using arbitrary cutoff values of single indicators
of adherence, and later examining the sensitivity of
imposed adherence group assignments by applying
other arbitrary adherence assignments. On the other
hand, the introduction of LCA in adherence research
has two main advantages: (i) it can answer the afore-
mentioned signiﬁcant measurement issues in determin-
ing the rates of nonadherence; and (ii) it will yield
more precise estimation of adherence patterns because
an appropriate LCA can classify patients based on
multiple proﬁles of adherence. Speciﬁcally, identiﬁca-
tion of adherence groups is enhanced by multiple
adherence indicators and their correlation/association
structure. As more adherence indicators are available
and the correlation/association of those indicators are
stronger (unlike the conventional way of adherence
assignment based on multiple adherence indicators
implicitly assumes independence among the indica-
tors), the advantages of LCA will be bigger.
Methods
Data
Data for this study were derived from a 100%-sample
of the paid claims data ﬁles for the fee-for-service
portion of the California Medicaid (Medi-Cal)
program from 1994 to mid-2003 (available through
the State of California Department of Health Services
Medical Care Statistics Section with legal and human
subject protection review approvals). The original data
set included all patient episodes of antipsychotic treat-
ment over this 10-year period. For this study, a patient-
level data set was created by taking the ﬁrst
antipsychotic treatment episode of each patient initi-
ated after January 1, 1999 to avoid some systematic
changes possibly caused by a Medi-Cal event in
October 1997 of removing prior authorization restric-
tion on atypical antipsychotic agents [9]. All patients
in the study sample had at least one claim with a
recorded diagnosis of schizophrenia (International
Classiﬁcation of Diseases, Ninth Revision [ICD-
9] = 295.0–295.9 or the word “schiz”) during the
study period (1999–2003).
These patient-level data included information on
previous treatment attempts during the 6-month
period before the index date (the start day of the ﬁrst
antipsychotic treatment episode initiated after January
1, 1999) with an exception of annualized number of
episodes (1994–index date), demographic characteris-
tics, medical and mental-health diagnostic proﬁles, and
prior use of health services. Patients were excluded in
the analysis if any of the following diagnoses was
found: nonschizophrenic psychosis (ICD-9 = 291.xx-
294.xx), bipolar disorder (ICD-9 = 296.00–296.19,
296.40–296.89), depression (ICD-9 = 296.20–296.39,
300.4x), other affective disorders (ICD-9 = 296.9x),
anxiety (ICD-9 = 297.xx, 300.xx), substance abuse
(ICD-9 = 303.xx-305.xx), personality disorder (ICD-
9 = 301.xx), dementia (ICD-9 = 290.xx), and other
mental-health diagnoses (ICD-9 = 299.xx, 302.xx,
306.xx-314.xx, 3216.xx). In addition, patients
younger than 18 years of age at the index date and
patients who used nursing home care before the index
date were excluded from the analysis. In total, 36,195
patients were selected for the LCA.
Statistical Methods
Latent class analysis was developed in the 1960s to
model attitudinal variables captured by social survey
items with categorical responses [10]. LCA is now
widely used and has become a standard tool for analy-
sis in social, psychological, and biomedical research
(see McCutcheon [11] for an elementary introduction,
and Hagenaars and McCutcheon [12] for a summary
of contemporary developments). Application of the
LCA model has been facilitated by developments in
statistical software. We used LatentGold 3.0 (Statisti-
cal Innovations, Inc., Belmont, MA, 2003) for LCA
estimation [13] and STATA 8.2 SE (STATA Corpora-
tion, College Station, TX, 2005) for the additional
statistical analyses.
For this study, an LCA cluster model was set up by
using only adherence proxy variables (see variables
subsection for more details) to interpret the identiﬁed
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clusters as adherence groups. Speciﬁcally, an LCA
cluster model with K-number of clusters can be
expressed as follows [13]:
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where yi and zi are a vector of the indicator variable
and a vector of covariates included in estimation
(active covariates) and x represents a latent class index
unobservable from the data (no distributional assump-
tion is needed). f (·|·) and p (·|·) denote conditional
probability density function and conditional probabil-
ity, i.e., P (x | ) is the mixing weight for conditional
density f (·| x). H is the number of subsets where local
independence (independent in this subset) among the
indicator variables holds. Once the parameters of the
latent class model had been estimated and class mem-
berships established (LatentGold 3.0 uses posterior
mode allocation to assign individuals to their most
likely latent class membership [14]), inactive covari-
ates of nonadherence were examined by proﬁling each
latent class in terms of demographic, clinical, and uti-
lization outcomes.
A difﬁculty in LCA cluster modeling is determining
the number of clusters, K. Because there is no domi-
nant criterion to choose the best model in terms of the
number of classes, it was determined by comparing
several criteria, including the likelihood ratio chi-
square statistic (L2) and information criteria such as
the Akaike’s information criterion (AIC), Bayesian
information criterion (BIC), Consistent Akaike’s infor-
mation criterion (CAIC), and sample size adjusted
Bayesian information criterion (ssaBIC). Information
criteria penalize more complex models for the number
of parameters, using different constants for model
penalty. The classiﬁcation error, which is measured by
the difference between the calculated class sizes by
assigning each individual proportionally to the esti-
mated probability of class membership and the modal
probability-assigned class sizes, was also reported.
Variables
Two types of variables were used in the LCA: 1) latent
class indicators of drug therapy adherence, and 2)
covariates (listed in Table 1).
Latent Class Indicators
The variables directly used in nonadherence latent
class estimation are listed in Table 2. These variables
are used to deﬁne or measure a latent index of adher-
ence. Three observable categorical adherence indica-
tors and two covariates were used in this study (see
Eq. 1):
1. a dichotomous adherence variable derived from the
medication possession ratio (MPR; cutoff value of
0.8 used; Gilmer et al. [1]) for all antipsychotics;
2. a variable of the number of prior treatment
attempts (ﬁve levels: 1, 2, 3, 4, 5); and
3. a variable documenting time to ﬁrst change in
antipsychotic medications during the ﬁrst post-
treatment year (ﬁve levels: no switch, time < 30,
30  time < 90, 90  time < 180, 180  time
< 365 days).
Covariates in the LCA
Two types of covariates are used in LCA: active cova-
riates and inactive covariates [15]. The former is used
Table 1 Patient characteristics (N = 36,195)
Patient demographics
Number of
patients Percentage
Age
18–25 1,917 5.3
25–35 6,154 17.0
35–45 11,386 31.5
45–55 9,634 26.6
55–65 4,598 12.7
65+ 2,506 6.9
Race
White 17,546 48.5
Black 6,785 18.8
Hispanic 1,590 4.4
Asian 1,351 3.7
Other/unknown 8,923 24.7
Male 19,505 53.9
Urban residence 28,309 78.2
Medi-Cal eligibility category
Disabled 30,630 84.6
Aid for dependent children 3,584 9.9
Old age assistance 479 1.3
Blind 122 0.3
Other aid categories 1,380 3.8
Prior use of health care (baseline)
Acute hospitalization 1,006 2.8
Psychiatric hospitalization 1,478 4.1
Ambulatory care services 23,546 65.1
Rehabilitation services 77 0.2
Community health center services 23,520 65.0
Suicide attempts 200 0.6
Annualized number of annual
treatment episodes
Number 1 5,822 16.1
1 < Number 2 12,018 33.2
2 < Number 3 8,115 22.4
3 < Number 4 4,444 12.3
Number > 4 5,796 16.0
Depot antipsychotic use 2,017 5.6
Annual health-care costs (follow-up) Average S.D.
Ambulatory outpatient care $1,117 $4,263
Prescription drugs $4,175 $4,666
Long-term care $584 $5,489
Acute hospitalization $317 $2,457
Psychiatric hospitalization $938 $8,085
Community mental health centers $2,524 $5,866
Total $9,888 $14,658
Use of institutional service in
follow-up period Percentage
Long-term care 2.0
Acute hospital admission 5.1
Psychiatric hospital admission 7.2
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in deﬁning the latent index, i.e., actively involved in the
estimation process, and the latter is used to proﬁle the
class but is not involved in the estimation process.
Active covariates can be also considered predictors to
determine whether they are associated with adherence
class memberships, whereas inactive covariates are
typically cross-tabulated with class memberships to
describe each class.
Active covariates
1. a variable relating to the duration of uninter-
rupted therapy (less than 15-day gap) for all
antipsychotics (ﬁve levels: duration < 30,
30  duration < 60, 60  duration < 120, 120 
duration < 365, duration > 365 days); and
2. a dichotomous variable of polypharmacy deﬁned
as the concomitant use of two or more antipsy-
chotic prescriptions for more than 60 days.
In this study, those variables involved in the LCA
cluster estimation (indicators and active covariates)
were limited to adherence proxy variables to reﬂect
multiple proﬁles of adherence while minimizing the
inﬂuences from other covariates not directly related to
adherence, i.e., our focus is on adherence grouping not
a mixed grouping of adherence and other covariates
such as age or cost. Thus, our model-building process
can be summarized as using adherence proxy variables
to ﬁnd a parsimonious LCA cluster model.
The inactive covariates used in this study include
demographic variables at treatment initiation (age,
sex, ethnicity, urban residence, and aid category), clini-
cal and resource use variables during 6 months before
the treatment initiation (e.g., dummy variables of
various health-care services), the annualized number of
prior episodes, and utilization outcome variables (cost
variable for each health-care service) during the
12 months after the treatment initiation. The 6 months
period before the treatment initiation and the
12 months period after the treatment initiation will be
referred to as the baseline period and the follow-up
period, respectively, for the remainder of this article.
Results
Characteristics of Study Population
The descriptive statistics of patient characteristics are
shown in Table 1. The majority of patients in this
study were 35 to 55 years of age (58.1%). Whites were
the largest ethnic group (48.5%) and the difference
between sexes was approximately 8% (female 46.1%
vs. male 53.9%). Most patients lived in urban areas
(78.2%) and had a disability (84.6%). During the
6 months before treatment initiation (baseline period),
few patients had acute hospitalization (2.8%) or psy-
chiatric hospitalization (4.1%). Most patients used
outpatient care (65.1%) and community mental-health
centers (65.0%). Patients had low rates of suicide
attempts (0.6%) and depot formulation use (5.6%).
Half of the patients (55.6%) had an annualized
number of treatment episodes greater than 1 but less
than or equal to 3.
During the 1-year follow-up period, the single most
costly health-care cost category was prescription drugs
($4175), followed by ambulatory care provided by
community mental-health centers ($2524), or physi-
cians and other community-based providers ($1117).
Use of institutional services was limited as only 2% of
patients used nursing home care ($584); 5.1% used
acute hospital services ($317) and 7.2% were admitted
to a psychiatric hospital or psychiatric service in a
community hospital ($938). The total average cost for
all services over the 1-year follow-up period was
$9888 (SD = $14,658).
The distributions of indicators and active covariates
used in the adherence estimation are shown in Table 2.
During the year after treatment initiation, approxi-
mately 43% of patients had anMPR equal to or greater
than 0.8, which implies that patients used at least
288 days of therapy during the ﬁrst treatment year (not
necessarily consecutive). Only 26% of patients,
however, had a minimum of 240 days of uninterrupted
drug therapy (not reported in Table 2). Additionally,
approximately 18% of the patients were switched to a
different antipsychotic agent. Taken together, these
results indicate that a signiﬁcant proportion of patients
experienced a period of nonadherence in excess of 15
Table 2 Distribution of adherence indicator variables and
active covariates
Number of patients Percentage
Indicator variables
Time to switch of antipsychotic
No switch in 1 year 29,775 82.3
Switched in <30 days 1,629 4.5
Switched in 30–<90 days 1,983 5.5
Switched in 90–<180 days 1,408 3.9
Switched in 180–<365 days 1,400 3.9
Medication possession ratio
<0.8 20,744 57.3
0.8 15,451 42.7
Number of treatment attempts
1 9,036 25.0
2 9,019 24.9
3 7,329 20.3
4 4,972 14.7
>4 5,839 16.1
Active covariates
Days of uninterrupted therapy
<30 2,549 7.0
30–60 12,029 33.2
60–120 7,028 19.4
120–365 8,409 23.6
365 6,080 16.8
Polypharmacy
Yes 2,941 8.1
No 33,254 91.9
Classifying Antipsychotic Adherence Using LCA 51
consecutive days during the treatment episodes, but
restarted their therapies relatively quickly.
Model Selection
Results for the one- to four-class LCA models using the
three indicators mentioned earlier and two active cova-
riates are presented in Table 3. All information criteria
(AIC, BIC, ssaBIC, and CAIC) indicated that the three-
class model had the lowest (best) values compared
with the other LCA models. This model was consid-
ered the best model and is therefore further demon-
strated in this section. One criterion that did not
support the three-class model was the likelihood ratio
chi-square statistic, which is conventionally used to
ﬁnd a model satisfying observed versus expected fre-
quencies P > 0.05, but the bootstrapped P-value of this
model was less than 0.01. This may have been caused
by the large sample size in this study, which favors a
higher number of clusters.
Adherence Classes
The model estimation results based on three latent
classes are presented in Table 4.
The nonadherent group (class 1, 64.5% of the
sample) had the lowest MPR values (86% had an MPR
less than 0.8). Class 2 was the partially adherent group
(20.7%) in which more than 91% of patients had an
MPR equal to or greater than 0.8, but 58% of patients
switched antipsychotic drug therapy. Class 3 was the
“adherent” group (14.8%) with more than 99% of its
patients having an MPR equal to or greater than 0.8.
The adherent group was unlikely to switch therapy as
more than 99% of patients in this group had only one
treatment attempt, i.e., all three indicators were almost
perfect markers of latent adherence. These results
suggest that patients who need to change medication
or augment their therapy are at much higher risk of
discontinuation.
Table 5 shows the proﬁle of each covariate for each
of the three latent class groups. There were some
noticeable characteristics in each group. Patients clas-
siﬁed into the nonadherent group were more likely to
be nonwhite female, and recipients of Aid for Family
with Dependent Children, i.e., a representative patient
in this group is a minority single mother with depen-
dent children. Nonadherent patients were also more
likely to use acute hospitalization and psychiatric hos-
pitalization in both baseline and follow-up periods.
The partially adherent group had the highest rate of
polypharmacy (34% vs. 2% in the nonadherent group
Table 3 Comparison of cluster analysis (active covariates: duration of therapy, polypharmacy)
No. of classes L2* BIC AIC ssaBIC CAIC
Degree
of freedom
Proportion of
classiﬁcation errors
1 57,395 215,592 215,515 215,563 215,601 579 0.000
2 31,347 189,606 189,479 189,558 189,621 573 0.033
3 17,721 176,043 175,864 175,976 176,064 567 0.053
4 12,542 179,390 179,160 179,304 179,417 561 0.104
*All the P-values of likelihood ratio statistic L2 are <0.01.
BIC, Bayesian information criterion; AIC, Akaike’s information criterion; ssaBIC, sample size adjusted Bayesian information criterion; CAIC, consistent Akaike’s information
criterion.
Table 4 Distribution of clusters: indicators
Cluster 1
(Nonadherent)
Cluster 2
(Partially adherent)
Cluster 3
(Adherent)
Cluster size 0.6452 0.2068 0.1479
Standard error (SE) (0.0029) (0.0032) (0.0012)
Indicators
Time to switch to another antipsychotics
0 Time to switch = 0 91% 42% 100%
1 Time to switch < 30 5% 7% 0%
2 30 Time to switch < 90 3% 17% 0%
3 90 Time to switch < 180 1% 16% 0%
4 180 Time to switch < 365 <1% 18% 0%
SE 0.0043 0.025 <0.0001
Medication possession ratio (MPR)
0 MPR < 0.8 86% 9% <1%
1 MPR 0.8 14% 91% >99%
SE 0.0035 0.0052 0.0015
Number of antipsychotic treatment attempts
1 Treatment attempts = 1 12% 12% 98%
2 Treatment attempts = 2 29% 29% 2%
3 Treatment attempts = 3 24% 24% <1%
4 Treatment attempts = 4 16% 16% 0%
5 Treatment attempts > 4 19% 19% 0%
SE 0.0089 0.0179 0.0039
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Table 5 Distribution of clusters: covariates
Nonadherent
(N)
Partially
adherent (P)
Adherent
(A)
P-value* (3-way
comparison)
P-value†
(N vs. P)
P-value†
(N vs.A)
P-value†
(P vs.A)
Active covariates
Duration of therapy <0.001 <0.001 <0.001 <0.001
<30 11% 1% 0%
30–60 49% 6% 0%
60–120 25% 15% 0%
120–365 15% 58% 14%
>365 <1% 19% 86%
Polypharmacy <0.001 <0.001 NA NA
No 98% 66% 100%
Yes 2% 34% 0%
Inactive covariates
Age <0.001 <0.001 <0.001 <0.001
18–25 6% 5% 3%
25–35 18% 16% 14%
35–45 32% 31% 31%
45–55 26% 28% 28%
55–65 12% 13% 14%
>65 7% 6% 9%
Race <0.001 <0.001 <0.001 <0.001
Asian 4% 3% 4%
African American 22% 15% 12%
Hispanic 5% 4% 3%
Other 24% 25% 25%
White 45% 53% 55%
Male 53% 55% 57% <0.001 <0.001 <0.001 0.041
Urban residence 79% 78% 78% 0.067 0.029 0.143 0.815
Medi-Cal aid category <0.001 <0.001 <0.001 0.024
AFDC 12% 7% 6%
Blind <1% <1% <1%
Disabled 83% 88% 89%
Old age assistance 1% 1% 2%
Other aid 4% 4% 4%
Use of health-care services
Long-term care (follow-up) 2% 3% 1% <0.001 0.122 <0.001 <0.001
Acute hospitalization (baseline) 3% 2% 2% <0.001 <0.001 <0.001 0.027
Acute hospitalization (follow-up) 6% 5% 3% <0.001 <0.001 <0.001 <0.001
Psychiatric hospitalization (baseline) 4% 4% 3% <0.001 0.236 <0.001 <0.001
Psychiatric hospitalization (follow-up) 8% 7% 3% <0.001 <0.001 <0.001 <0.001
Ambulatory outpatient care (baseline) 65% 66% 65% 0.026 <0.001 0.234 0.06
Ambulatory outpatient care (follow-up) 75% 80% 76% <0.001 <0.001 0.025 <0.001
Community mental-health center use (baseline) 64% 68% 66% <0.001 <0.001 <0.001 0.003
Community mental-health center use (follow-up) 71% 76% 71% <0.001 <0.001 0.635 <0.001
Annualized number of episodes (1 year) <0.003 <0.001 <0.001 <0.001
1 18% 20% 28%
2 18% 21% 26%
3 19% 21% 21%
4 21% 21% 15%
>4 23% 18% 10%
Suicide attempts 1% 1% 0% 0.013 0.154 0.004 0.06
Prior suicide attempts 4% 4% 1% <0.001 0.04 <0.001 <0.001
Follow-up depot formulation use 5% 10% 1% <0.001 <0.001 <0.001 <0.001
Follow-up health-care costs (SD‡)
Ambulatory outpatient care $1,170
($4,390)
$1,121
($3,846)
$877
($4,253)
<0.001 0.123 <0.001 0.001
Prescription drugs $3,355
($4,427)
$6,119
($5,040)
$5,033
($4,094)
<0.001 <0.001 <0.001 <0.001
Long-term care $579
($5,489)
$827
($6,356)
$268
($3,981)
<0.001 <0.001 <0.001 <0.001
Acute hospitalization $371
($2,767)
$265
($1,961)
$158
($1,446)
<0.001 <0.001 <0.001 0.002
Psychiatric hospitalization $992
($7,212)
$1,134
($10,793)
$433
($7,194)
<0.001 0.241 <0.001 <0.001
Community mental-health centers $2,301
($5,515)
$3,350
($7,001)
$2,338
($5,504)
<0.001 <0.001 0.63 <0.001
Total $8,988
($14,280)
$13,050
($16,774)
$9,396
($12,374)
<0.001 <0.001 <0.001 <0.001
*Three-way comparison P-values were calculated by estimated class membership by the modal conditional probability for each patient. Chi-square test (r ¥ c extended Fisher’s
exact test) was used for categorical variables (if any cell with <5% frequency) and ANOVA F-test was used for continuous variables.
†Pairwise comparison P-values were calculated by chi-square test (Fisher’s exact test) for the categorical variables (if any cell with <5% frequency) and t-test for the continuous
variables.
‡Standard deviations were calculated by modal probability assignment of each patient into an adherence group.
AFDC,Aid for Family with Dependent Children.
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and 0% in the adherent group), of depot formulation
use (10% vs. 5% in the nonadherent group and 1% in
the adherent group), of long-term care in the follow-up
period, and the highest outpatient care use and com-
munity mental-health center use in both the baseline
and the follow-up periods.
The adherent group was more likely to be white,
male, and included a slightly higher number of seniors.
Adherent patients also had the lowest rates of acute and
psychiatric hospitalizations, suicide attempts, number
of treatment episodes, depot drug use, and polyphar-
macy. All the covariates show signiﬁcant difference at
the 5% level in three-way comparison among the adher-
ence classes except for urban residence.
Figure 1 shows a comparison of cost outcomes
among the three latent classes. The total cost for the
12-month period after the index prescription was cal-
culated for each patient and then averaged by each
latent class. Interestingly, the nonadherent group
showed the lowest average total cost ($8988) and the
partially adherent group showed the highest average
total cost ($13,050). The low average total cost for the
nonadherent group was achieved despite the high rate
of acute and psychiatric hospitalizations in the
follow-up period. The adherent group has a lower
average cost than the nonadherent group in all the cost
categories except drug cost ($1678 higher) and com-
munity mental-health care center cost ($37 higher).
The partially adherent group dominated the adherent
group in all the cost categories and had the highest
average costs in drugs, long-term care, psychiatric hos-
pitalization, and community mental-health centers.
Discussion
Although conventional adherence research would have
categorized patients as adherent or nonadherent using
MPR in an arbitrary manner, the use of LCA in this
study has helped identify three unique empirically
derived adherence groups. If one were to group the
patients by MPR equal to or greater than 0.8, as is
typically done in adherence research, 42.7% of
patients would have been deﬁned as adherent whereas
LCA identiﬁed only 14.8% as adherent. This differ-
ence could mean that LCA helped identify a subgroup
of high-cost patients (labeled as partially adherent
group), who could not be distinguished from the
adherent group when using the conventional deﬁnition
of adherence by MPR. Note that approximately 91%
of the partially adherent group had an MPR equal to
or greater than 0.8.
This study found that approximately two-thirds of
the schizophrenia patients (64.5%) enrolled in the
Medi-Cal program was nonadherent with their antip-
sychotic regimens. This rate is consistent with previ-
ous nonadherence rates reported in the literature,
which ranged from 40% to 70% [16]. Nevertheless,
the LCA estimated rate of full adherence found here
based on MPR and four other proxies of adherence
(14.8%) was much lower than that of a recent study
among Medi-Cal beneﬁciaries with schizophrenia in
San Diego County, California, which was based only
on MPR (41%, Gilmer et al. [1]). While 91% of par-
tially adherent patients in this study and almost
100% of adherent patients had an MPR equal to or
greater than 0.8, the identiﬁcation of three adherence
groups by the LCA techniques has taken into account
other proﬁles of adherence, such as the number of
treatment attempts, switching drug therapy, polyp-
harmacy, and duration of drug therapy. Hence, this
study demonstrated that LCA is a useful methodol-
ogy for estimating a typology of medication adher-
ence, thus expanding its already wide applicability in
medical research [17,18] and demonstrating its utility
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in the study of adherence to antipsychotic medica-
tions in the treatment of patients with schizophrenia.
Current ﬁndings suggest that interruptions or
changes in therapy before 90 days is a key indicator of
nonadherence. Partially adherent patients frequently
stay on their initial medication beyond 90 days, after
which they discontinue therapy for a short time
(>15 days), resulting in 44%of these patients switching
to a different medication. Although the MPR for these
partially adherent patients are typically greater than
80%, this group of patients may require greater atten-
tion from clinicians to help minimize gaps in therapy
and facilitate a seamless transition to alternative drugs.
Nonadherent and partially adherent patients exhib-
ited higher rates of utilization for all categories of
health-care utilization other than medication utiliza-
tion compared with adherent patients. Similar to
results in Gilmer et al. [1], however, the total treatment
cost over the 1-year follow-up period was higher for
adherent patients because substantial drug costs.
Nevertheless, any increase in costs associated with
medication adherence must be balanced by the well-
documented adverse consequences associated with
nonadherence in other important areas, namely the
reductions in patient well-being, disruptions of the
therapeutic alliance between the patient and the phy-
sician, increased substance abuse [19], and increased
hospitalization [1], all of which have long-term eco-
nomic consequences.
The number of antipsychotic treatment attempts
and time to change in antipsychotic medications
reported here may be biased because of the exclusion
of patients with gaps in their Medi-Cal paid claims
history of more than 90 days. Speciﬁcally, well-
functioning, continuously eligible Medi-Cal patients
with schizophrenia may have been excluded. These
patients would have been identiﬁed as having low cost
and classiﬁed as nonadherent had they remained in the
analysis. These patients would have increased the esti-
mated difference in cost between adherent and nonad-
herent patients in favor of the nonadherent group. For
example, a study on the health-care utilization of
Michigan Medicaid enrollees with schizophrenia [20]
reported an average total treatment cost of $14,512 in
the follow-up period. If nursing home residents at
treatment initiation are not excluded, the correspond-
ing cost increases from $9888 to $13,786. Because
nursing home patients tend to be adherent as a result
of medication oversight provided in such environ-
ments, it may be more appropriate to exclude them in
studies investigating the role of adherence. Another
issue related to sample size is that a large sample size
can affect the statistical signiﬁcance. Some of signiﬁ-
cant differences reported in Table 5 may have been
driven by the large sample size.
The prior use of depot formulations was found to
be associated with nonadherence and partial adher-
ence to oral antipsychotic medication. This is not sur-
prising because these depot formulations are often
used to treat patients with recurring adherence prob-
lems. Moreover, prior depot use can be used as a risk
factor to identify patients who may beneﬁt from closer
adherence monitoring. Unfortunately, our study analy-
sis was not able to track the depot-use patterns over
time, because of anomalies in paid claims database
for these medications [21], as data for days supply
recorded on prescription claims for depot formulations
are typically unreliable. This is a common problem
with prescriptions for injectable medications. Second,
multiple-dose depot prescriptions are commonly
stored at the physician’s ofﬁce or other outpatient
facilities and are frequently used to treat other patients
once the vial has been opened. This practice makes it
impossible to document medication adherence based
on pharmacy purchase of reﬁlls. There is a clear need
either to better identify the pattern of depot drug use in
the Medi-Cal database or to ﬁnd a new database suit-
able for analyzing such types of drugs.
Despite inherent limitations associated with paid
claims data, LCA analysis was able to combine mul-
tiple widely used indicators of adherence based on
medication reﬁll record into a single model, and these
adherence indicator-classiﬁed individuals to groups
differing in adherence behaviors, with high accuracy
(low classiﬁcation error). Our typology of three patient
adherence groups is supported by ﬁndings of outcomes
in health-care utilization in a similar environment [1].
When data of patient-reported and clinician-reported
adherence were available for the LCA analysis, a phy-
sician rating along with other three factors (e.g., sub-
stance abuse, recent hospitalization) deﬁnes adherence
groups that may be targeted for intervention [22].
Further exploration of the utility of LCA in a clinically
based, prospective study is warranted because it would
enable the inclusion of additional adherence measures,
such as self-report (patient or clinician), electronic
devices, and review of prescription records or claims,
to more accurately describe patients’ adherence to
medication regimens than LCA based on paid claims
data.
Conclusions
This study identiﬁed latent classes related to adher-
ence, partial adherence, and nonadherence using LCA.
Three observable indicators of medication adherence
(time to switch antipsychotic therapy, MPR, and
number of treatment attempts) along with two active
covariates (duration of antipsychotic therapy and
polypharmacy) were used to construct a latent class
index for adherence. Despite the need for continuous
treatment with antipsychotic medications in the care of
schizophrenia patients, there were high rates of non-
adherence and partial adherence among patients with
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schizophrenia covered by Medicaid. The adverse con-
sequences associated with nonadherence and partial
adherence call for closer patient monitoring to tailored
interventions to improve patients’ adherence to antip-
sychotic treatment regimens.
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